PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8037760-5	1994	Thus, the results indicate that sustained administration of IL-1ra can prevent the diabetogenic process elicited by low dose STZ treatment, suggesting that IL-1 may have a role in the pathogenesis of this form of diabetes.	Streptozocin	125-128	interleukin 1 complex	Mus musculus	60-64	
21458563-4	2011	After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice.	Streptozocin	95-98	interleukin 1 complex	Mus musculus	51-55	
8080048-1	1994	By administering physiological doses of interleukin-1 (IL-1) concurrently with multiple low doses of the beta cell toxin streptozotocin (MSZ), we observed an augmentation of diabetes by IL-1 in four different strains of mice.	Streptozocin	121-135	interleukin 1 complex	Mus musculus	186-190	
24076200-8	2013	Together, these findings revealed that RMP treatment effectively attenuated STZ-induced cytotoxicity in renal tissue, in which RMP-exerted renoprotection was associated with intrarenally debilitating inflammation reaction through blocking the IL-1/NF-kappaB pathway, thereby maintaining the renal homeostasis.	Streptozocin	76-79	interleukin 1 complex	Mus musculus	243-247	
14693703-7	2004	IL-1 reportedly makes an important pathological contribution in the multidose streptozotocin model of diabetes; however, there was no difference in sensitivity to streptozotocin between NOD mice and NOD.Casp1(-/-) mice at 40 mg/kg body wt or at 25 mg/kg body wt dosage levels.	Streptozocin	78-92	interleukin 1 complex	Mus musculus	0-4	
2668949-5	1989	Furthermore, IL-1 markedly reduced the levels of triglycerides in blood of streptozotocin-induced diabetic mice at later stages of the disease.	Streptozocin	75-89	interleukin 1 complex	Mus musculus	13-17